Medicamen Organics Ltd. · NSE:MEDIORG
Medicamen Organics — Investor Presentation (October 2024)
42 slides from Medicamen Organics's investor presentation, Oct 22, 2024
Slide 1: Investor Presentation filing letter to NSE
@ MEDICAMEN Organics Limited Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-Il, Delhi-110052 (India) \\/ Tel: 011-27430249, 27138171 E-mail: info@mediorganics.in | CIN No: L74899DL1995PLC066416 | GSTIN:07AABCM4302P1ZF October 22, 2024 To, National Stock Exchange of India Limi
Slide 2: Slide 2
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Medicamen Organics Limited (“*“MOL”, The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and s
Slide 4: Company Overview
Company Overview
Slide 5: Medicamen Organics Limited Expanding Horizons In Pharma Market
Medicamen Organics Limited Expanding Horizons In Pharma Market Medicamen Organics Limited specializes in the development, manufacturing, and distribution of pharmaceutical products which includes tablets, capsules, syrups and ointments. The company Provides contract and third-party manufacturing ser
Slide 6: Vision & Mission
Vision & Mission Mission Vision To pioneer advancements in medicine by To create a healthier world where leveraging cutting-edge research and technology. innovative medications positively The company aspire to be a global leader in impact the lives of patients and pharmaceutical innovation, setting
Slide 7: Key Facts & Figures
Key Facts & Figures medicamen %fi — ©) Sf — [ 25+ S 170+ 80+ Years Of Experience Product Category Products For Export Domestic Products = i ISO 9001:2015 2 21,600 12+ Annual Installed Certified Company Manufacturing Team Size Capacity Facilities (in Lakh tablets) FY24 (Audited) Revenue EBITDA PAT % 2
Slide 8: Key Milestones In MOL's Journey
Key Milestones In MOL’s Journey * Reconstructed Unit I, creating a 20,000 sq. ft. area for producing o * Incorporated as various pharmaceutical products and E::ezog,:p:gg £ "Panchdeep ) received the necessary Emerge Platform Pharmaceutlcals manufacturing licenses and WHO * Companyalso Limited" and r
Slide 9: A Legacy Of Excellence
A Legacy Of Excellence Export Award Pharmexcil Award for Commerce & Industry Presented By: Hon'ble Shri Pranab Mukherjee, Former Category: "Fast Emerging President of India Company” Year: 2015 Year: 2008-09 Investor Presentation
Slide 10: Business Overview
Business Overview
Slide 11: Contract Manufacturing: B2B Partnerships
Contract Manufacturing: B2B Partnerships MOL Specializes In B2B Co Compa Key Highlights -» Market Presence Ownership Structure Product Portfolio - Current Partnerships Operations in key markets, The company owns the 84 Product including India, with strong 38 Domestic partners and development and man
Slide 12: Contract Manufacturing: Government Contract
Contract Manufacturing: Government Contract Active Participation In Government Tenders To Supply Products To Various Government Entities, Including Hospitals, Departments, Psus, & Armed Forces. Advantages The Company Have Supplied To 11 Government Institutions Diverse Revenue Streams /‘ Mix of B2B p
Slide 13: From Health To Wellness: Product Categories
From Health To Wellness: Product Categories medicamen Capsules: Targeted Treatments for Diverse Tablets: Health Needs MOL manufactures a variety of Focused on developing iron @ capsule formulations, tailored to supplements to address common address specific health nutritional deficiencies conditions
Slide 14: From Health To Wellness: Product Categories
From Health To Wellness: Product Categories Ointments and External Dry Powder Sachets: Preparations: Convenient Dosage Form Specialized Topical Solutions Company’s portfolio includes a Innovative sachets designed for wide range of topical antifungal easy administration and and antibacterial formulat
Slide 15: From Health To Wellness: Product Categories
From Health To Wellness: Product Categories Syrups/Suspension Diverse Range of Oral Liquids MOL excels in developing and manufacturing a variety of oral liquid formulations, designed for different therapeutic needs Cough Syrups A comprehensive range to address various types of cough and respiratory
Slide 16: Strategic Facilities: Combining Quality & Flexibility
Strategic Facilities: Combining Quality & Flexibility The Company operates two advanced manufacturing facilities strategically located in Haridwar, designed to ensure the efficient production of high-quality pharmaceutical products. Company’s facilities are equipped with cutting-edge machinery and r
Slide 17: Strategic Facilities: Combining Quality & Flexibility
Strategic Facilities: Combining Quality & Flexibility ! ‘.; ! ) 4 - Tablets (in Lakh) Suspension (In Litre) 9,36,000 Capsules (in Lakh) 780 Ointment (InKg) 93,600 Dry Powder Sachets (in No) 37,44,000 Investor Presentation «(6)»
Slide 18: Broadening Global Presence: Current & Future Markets
Broadening Global Presence: Current & Future Markets G-} A Current International Presence ‘,0‘.,1 Congo Myanmar Benin Mozambique Cameg Burundi Togo Kyrgyzstan Senegal Kenya Burkina Faso Philippines Future Plans Of Geographical Expansion Mauritius Tanzania Rwanda Cameroon Sierra Leone Ivory Coast Nep
Slide 19: Strategic Partnerships: Building Success Together
Strategic Partnerships: Building Success Together medicamen GRYVETY EUIOPA Dr. Morepen” Mgz= Biocare Pvt. Ltd. MAY & BAKER JASBAL PHARMA PHARMACEUTICALS LTD. sockens | formimimt | SIS | KKnoll ENAY s ™\~ . o, Beotoctiem d KILITCH DRUGS D ajanta pharma limited Lean BioPharma PVt Ltd. it © SHREYA 7 Fo
Slide 20: Growth Strategies
Growth Strategies
Slide 21: Strategic Growth & Expansion Initiatives
Strategic Growth & Expansion Initiatives The company is transitioning from its As part of its global expansion strategy, MOL plans traditional export model to marketing to enter the selected African countries such as its own brands in international Rwanda, Francophone countries, Tanzania etc. with m
Slide 22: Expansion Into Francophone Africa
Expansion Into Francophone Africa Francophone Africa Is An Attractive Region For Expansion Due To Rising Demand For Pharmaceuticals, Driven By Populati Healthcare Initiatives, & Regional Efforts Like The West African Common Market Also Enhance Access & Boost Pharmaceutical Spen 980 MOL plans to tap
Slide 23: Strategic Investment: Expanding Horizons In Rwanda
Strategic Investment: Expanding Horizons In Rwanda G-) MOL Selected Rwanda For Its Expansion Due To Strategic Location For Piloting Operations In East Africa, Safe Business Environment And The Country's High Accounting Standards. Rwanda's Cashless Economy Ensures Secure Transactions, Allowing For Lo
Slide 24: Management Overview
Management Overview
Slide 25: Experienced Promoters
Experienced Promoters medicamen Mr. Bal Kishan Gupta Mr. Ashutosh Gupta Chairman cum Managing Director Whole Time Director 40+ Years Of Experience 19+ Years Of Experience Mr. Bal Kishan Gupta, a seasoned Ashutosh Gupta, aged 43, holds a degree in professional with extensive experience in the Busines
Slide 26: Board Of Directors
Board Of Directors » Mrs. Sneh Gaur Mr. Sachin Gupta Mr. Rajinder Kumar Gupta Mr. Rakesh Kumar Director Independent Director Independent Director Independent Director 08+ years of experience 20+ years of experience 30+ years of experience 25+ years of experience Mrs. Sneh Gaur, is a Mr. Sachin Gupta
Slide 27: Industry Overview
Industry Overview
Slide 28: Indian Pharmaceutical Industry
Indian Pharmaceutical Industry India ranks 37 The country has an According to Major Segments of the Pharmaceutical is one of worldwide for established domestic Government data, the Pharmaceutical the top ten attractive pharmaceutical pharmaceutical Indian pharmaceutical Industry are Generic sectors
Slide 29: Indian Pharmaceutical Export Market
Indian Pharmaceutical Export Market Contract Research & Manufacturing Services (CRAMS) Contract research and manufacturing services is one of the fastest growing segments in the pharmaceutical and biotechnology industry. The pharmaceutical market uses outsourcing services from providers in the form
Slide 30: Industry Growth Drivers
Industry Growth Drivers (=D IPR & Innovation Global Regulatory Approvals Export Strength Product innovation and strong intellectual International plant approvals from stringent significant exports to regulated markets property rights through patents and authorities like US FDA, EMA, and PMDA, (USA,
Slide 31: Financial Overview
Financial Overview
Slide 32: Key Financial Highlights
Key Financial Highlights Total Income mEBITDA mPAT —EBITDA Margin —PAT Margin 19% 476 2,529 2% 10% 2,296 7% 5% 2,18 0.5 Fy22 FY23 FY24 Fy22 FY23 FY24 FY22 FY23 FY24 All Figures In X Lakhs & Marginin % Investor Presentation <G>
Slide 33: Profit & Loss Statement
Profit & Loss Statement InX Lakhs LELCTETS FY22 FY23 FY24 Revenues 2,098 2,215 2,527 Other Income 21 82 2 Total Income 2,119 2,296 2,529 Raw Material Expenses 1,566 1,580 1,580 Employee Costs 287 317 335 Other Expenses 128 132 138 Total Expenditure 1,981 2,028 2,053 EBITDA 138 269 476 Finance Costs
Slide 34: Balance Sheet
Balance Sheet InX Lakhs Equities & Liabilities FY22 FY23 FY24 Assets FY22 FY23 FY24 Equity 600 600 860 Non Current Assets Reserves 147 269 666 Fixed Assets 1,033 982 1,050 Net Worth 747 869 1,526 Non Current Investments Non Current Liabilities Other Non Current Financial Assets Long Term Borrowings
Slide 35: Cash Flow Statement
Cash Flow Statement InX Lakhs rticula FY22 FY23 FY24 Cashflow From Operations -9 -62 -261 Cashflow From Investments -59 -28 -139 Cashflow From Financing 23 929 401 Net Cash Flow -46 9 1 Opening Cash & Cash Equivalent 920 45 54 Closing Cash & Cash Equivalent 45 54 55 Investor Presentation 4@;
Slide 36: Consolidated Key Ratios
Consolidated Key Ratios ROE in% Debt To Equity In Times Book Value In2 . 137 136 17.74 13.35 14.49 15.50 083 106 Fy22 FY23 Fy24 FY22 FY23 Fy24 Fy22 FY23 Fy24 ROCE " In% Interest Coverage In Times i EPS 347 ™ 14.46 623 021 2.09 313 351 154 . —o Fy22 FY23 Fy24 Fy22 FY23 Fy24 Fraz Fr2s Fy24 Note: Debt
Slide 37: Revenue Breakdown: Government Contracts & Contract Manufacturing
Revenue Breakdown: Government Contracts & Contract Manufacturing ) In% FY22 FY23 FY24 3% 2% B Government Contract B Contract Manufacturing In X Lakhs Particulars Fy22 FY23 FY24 Government Contract 72 361 57 Contract Manufacturing 2,026 1,854 2,470 Total 2,098 2,215 2,527 Investor Presentation < @>
Slide 38: Product Category Wise Revenue Bifurcation
Product Category Wise Revenue Bifurcation FY22 FY23 FY24 S M Tablet M Ointments M capsules Other Products & Other Operating Revenue In X Lakhs Fy22 FY23 FY24 Tablet 1,505 1,107 1,597 Ointment 365 298 487 Capsules 88 498 29 Other operating Revenues 54 142 274 Suspension 53 14 20 Dry Powder Sachet 33
Slide 39: Share Holding Pattern and Share Performance
As on 30-09-2024 20,00,000 o 15,00,000 10,00,000 5,00,000 5 25 G o 2[} y2-100-22 5] $2-100-02 52.50 £ <S $2-100-81 o ¥2-100-91 3 s $2-200-v1 2[} y2-10-2l o € $2-100-01 H Public <S are Holding Pattern o ¥2-100-80 u $2-190-90 $2-30-70 $2-100-20 ve-des-0g ve-des-gz ve-des-92 ve-des-ve ve-des-gzz ve-des
Slide 40: SWOT Analysis
SWOT Analysis Strength Weakness o Good relations with established distributors o Dependencyon buyers o Wide range of registered products o Lack of Brand Awareness o Wide range of products under registration o Lack of firm arrangements Opportunities Threats o Expanding new geographical markets o Fluc
Slide 41: Investment Rationale
Investment Rationale Diverse Product Portfolio Strategic Market Expansion Contract Manufacturing Expertise The company boasts a broad range of Recently, the company initiated direct The company has established itselfas a pharmaceutical products, including exports to new markets like Burundi and trus
Slide 42: Thank You
Medicamen Organics — Investor Presentation (October 2024) on 6ix